Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials

<table>Kaplan-Meier estimated overall survival is shown for patients treated with survivin-2B80–88 peptide plus IFA (Study 1) versus survivin-2B80–88 peptide plus IFA in combination with IFA alpha (Study 2). IFA: incomplete Freund’s adjuvant; IFN: interferon.</table>

Journal of Immunology Research

fig3

Figure 3

Figure 3: Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials 

Figure 3 | Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials 